地塞米松拮抗紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的实验研究
|
摘要
近年来紫杉醇联合顺铂的化疗方案(PT方案)已广泛应用于临床治疗卵巢癌,尤其是卵巢癌晚期无法手术的姑息治疗、一线化疗失败或多次化疗失败的转移性卵巢癌,为了防止化疗时紫杉醇药物发生严重的过敏及恶心呕吐等反应,在接受化疗前的所有患者应事先进行地塞米松预防用药。但近来许多研究表明,地塞米松能选择性抑制紫杉醇诱导一些肿瘤细胞的凋亡,下调机体的免疫反应,导致肿瘤组织转移,影响紫杉醇在恶性肿瘤化疗中的疗效,那么地塞米松对紫杉醇诱导卵巢癌细胞凋亡的作用如何,是否拮抗紫杉醇诱导卵巢癌细胞凋亡从而降低紫杉醇的疗效?因此,本项目以人卵巢癌细胞株SKOV-3为材料,通过体外实验探讨地塞米松预处理对紫杉醇诱导卵巢癌细胞凋亡产生的影响、发生的可能机制,并建立SKOV-3裸鼠移植瘤,通过体内实验进一步探讨地塞米松对紫杉醇抗肿瘤疗效的影响,对今后在临床工作中如何正确认识和使用地塞米松以及开发紫杉醇的给药途径必将产生深远的影响。
第一部分地塞米松对紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的保护作用
目的探讨地塞米松(Dex)对紫杉醇(PTX)抑制人卵巢癌细胞株SKOV-3细胞增殖及诱导SKOV-3细胞凋亡的影响。
方法(一)MTT法测定细胞增殖
1、用含不同浓度紫杉醇(10 nM、20 nM、50 nM、100nM)的培养液培养SKOV-3细胞24小时,测定紫杉醇对SKOV-3细胞增殖的影响。
2、用不同浓度地塞米松(0、0.001 uM、0.01 uM、0.1 uM、1uM)对SKOV-3细胞进行预处理24h后,每组中分别再用含不同浓度的紫杉醇(0、10 nM、20 nM、50 nM、100nM)培养液培养细胞24h,测定不同浓度的地塞米松对不同浓度的紫杉醇进行预处理后对SKOV-3细胞增殖的影响。
(二)TUNEL联合DAB染色从形态学观察地塞米松对紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的影响。
(三)PI单染法测定地塞米松对紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡及细胞周期的影响。
结果(一)PTX能够抑制人卵巢癌细胞株SKOV-3细胞增殖,且与PTX的浓度有关,浓度越高,抑制率越大。
(二)0.001～1uM浓度范围内地塞米松对紫杉醇抑制人卵巢癌细胞株SKOV-3细胞增殖有不同程度的保护作用。
(三)TUNEL法联合DAB染色进行形态学观察,对照组中极少见到凋亡细胞,PTX组出现大量DAB染的胞核呈棕黄色的凋亡细胞,表现为核固缩,染色质边聚,凝集成块,并可见散在棕色的凋亡小体。但预先用地塞米松进行处理后再用PTX处理组出现凋亡细胞较单用紫杉醇明显减少。凋亡指数(AI)在对照组和Dex组分别为3.5±0.25%和4.0±0.26%两组间无差异,在Dex+PTX组与PTX组为11.7±1.72%和30.8±1.15%,两组与对照组比较差异显著(P＜0.01),且Dex+PTX组与PTX组比较,Dex+PTX组凋亡指数降低,有明显差异(P＜0.01)。
(四)PI单染检测细胞凋亡率表明地塞米松进行预处理后再用紫杉醇组细胞凋亡率为5.55±0.53%较单用紫杉醇组细胞凋亡率13.90±1.62%明显降低(P＜0.01),而且在地塞米松拮抗紫杉醇诱导SKOV-3细胞凋亡中,用地塞米松预处理后再用紫杉醇组与单用紫杉醇组比较,细胞周期中G2/M期无明显差异(P＞0.05)。
结论(一)地塞米松对紫杉醇抑制人卵巢癌细胞株SKOV-3细胞增殖有保护作用,且与地塞米松的给药浓度有关。
(二)地塞米松能拮抗紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡,但与细胞周期中G2/M期停滞无关。
第二部分地塞米松拮抗紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的可能机制
目的从IAP家族中抗凋亡基因Survivin和Bcl-2家族中抗凋亡基因Bcl-2、Bcl-X_L两条通路,探讨地塞米松拮抗紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的可能机制,并为下一步的动物实验奠定基础。
方法将细胞用不同药物处理后,用半定量RT—PCR检测凋亡相关基因Bcl-2、Bcl-X_L and Survivin mRNA的表达。Western blot检测Bcl-X_L和末端半胱氨酸蛋白酶Cleaved-caspase-3蛋白的表达。
结果(一)用地塞米松进行预处理后再用紫杉醇组(Dex+PTX组)与单用紫杉醇组(PTX组)比较,Dex+PTX组Bcl-X_L mRNA、Survivin mRNA的表达明显高于PTX组(P＜0.01)。
(二)Bcl-2蛋白家族成员Bcl-2 mRNA的表达:Dex组和Dex+PTX组Bcl-2蛋白家族成员Bcl-2 mRNA的表达较对照组无差异(P＞0.05),Dex+PTX组与PTX组之间比较也无差异(P＞0.05)。
(三)Bcl-X_L蛋白水平表达:Dex组较对照组升高(p＜0.01),而且用地塞米松进行预处理后再用紫杉醇组(Dex+PTX组)与单用紫杉醇组(PTX组)比较,Dex+PTX组Bcl-X_L蛋白表达明显高于PTX组(P＜0.01)。
(四)Cleaved caspase-3蛋白水平表达:Dex组和Dex+PTX组较对照组明显降低(p＜0.01),而且用地塞米松进行预处理后再用紫杉醇组(Dex+PTX组)与单用紫杉醇组(PTX组)比较,Dex+PTX组Cleaved caspase-3蛋白表达明显低于PTX组(P＜0.01)。
结论地塞米松对紫杉醇的抗凋亡作用可能通过上调IAP家族中Survivin和Bcl-2家族中Bcl-X_L抗凋亡基因的表达,下调caspase3活性,从而抑制人卵巢细胞株SKOV-3细胞凋亡。
第三部分地塞米松在人卵巢癌细胞株SKOV-3裸鼠移植瘤中对紫杉醇抗肿瘤疗效的影响
目的通过建立人卵巢癌细胞株SKOV-3裸鼠移植瘤模型进行体内实验,评价地塞米松进行预处理后,对紫杉醇抗肿瘤作用的影响,并进一步分析其作用机理。
方法(一)建立人卵巢癌细胞株SKOV-3裸鼠移植瘤的模型。
(二)分组及给药:(1)对照组:生理盐水(含0.001%无水乙醇),腹腔内注射;(2)地塞米松组:1mg/kg,腹腔内注射;(3)紫杉醇组:20mg/kg,尾静脉注射;(4)地塞米松+紫杉醇组:在其它三组给药前12小时,预先给予地塞米松1mg/kg,腹腔内注射,然后给予紫杉醇20mg╱kg,尾静脉注射。三天一个疗程,共6个疗程。
(三)观察移植瘤的生长,绘制裸鼠移植瘤的生长曲线,实验结束称瘤体的重量,计算肿瘤生长抑制率。
(四)免疫组化分析:Bcl-X_L和Cleaved caspase-3蛋白的表达,细胞增殖标记物Ki-67的表达。
(五)光镜和透射电镜下观察组织形态和细胞超微结构改变。
结果(一)在紫杉醇对SKOV-3裸鼠移植治疗中,用地塞米松进行预处理后再用紫杉醇组,移植瘤的体积较单用紫杉醇组增大(P＜0.01)。
(二)治疗结束后称瘤重,Dex+PTX治疗组瘤重为0.79±0.09g,PTX组瘤重为0.50±0.08g,Dex+PTX组较PTX组瘤重升高(P＜0.01)。Dex+PTX组和PTX组抑制率分别为45.14%和65.28%,PTX组较Dex+PTX组抑制率大约增加18—25%。
(三)HE染色后,PTX治疗组绝大部分细胞变大,细胞质较其它组明显减少,细胞表现为空泡和凋亡特征。在Dex+PTX组中也有一些细胞表现为空泡和凋亡特征,但明显少于PTX组。电镜下Dex+PTX组和PTX组可见核固缩,染色质边聚,凝集成块等细胞凋亡征象,但Dex+PTX组中细胞凋亡征象少于PTX组。
(四)免疫组化结果表明,Dex+PTX组与PTX组相比,在Dex+PTX组中Ki-67细胞增殖标记物、Bcl-X_L蛋白表达升高,Cleaved caspase-3蛋白表达降低,有显著性差异,P＜0.0125。
结论(一)体内实验证实地塞米松能降低紫杉醇对人卵巢癌SKOV-3裸鼠移植瘤治疗效果。
(二)体内实验证实地塞米松能拮抗紫杉醇诱导的人卵巢癌SKOV-3裸鼠移植瘤细胞凋亡,可能通过上调Bcl-2家族中Bcl-X_L抗凋亡基因,下调Cleaved-caspase3的活性。
In recent years,the chemotherapy of paclitaxel combined cisplatin has been widely used in the treatment of ovarian cancer,particularly for advanced that could not be operated,drug-refractory and metastatic ovarian cancer.Dexamethasone was routinely used as a premedication in the clinical applicantion of paclitaxel to prevent hypersensitivity and nausea.However,recently studies discovered that dexamethasone could selectively inhibit paclitaxel-induced apoptosis in a number of human solid tumor cells.It can downregulate the immune response and contribute to tumour metastasis.Pretreatment with dexamethasone interfered with the therapeutic efficacy of Paclitaxel.How is the influence of dexamethasone on paclitaxel-induced apoptosis in ovarian cancer cells? If dexamethasone can inhibit paclitaxel-induced apoptosis in ovarian cancer cells and reduce the therapeutic efficacy of paclitaxel.Therefore,we performed in vitro experiments with human ovarian cancer SKOV-3 cell line to evaluate the effects and mechanisms of dexamethasone on human ovarian cancer cell apoptosis induced by paclitaxel and to explore the influence of dexamethasone on antitumor therapeutic efficacy of paclitaxel in vivo through development of animal models bearing ovarian xenograft tumor.This finding may have a potential implication on how to use correctly dexamethasone in the clinical practice and to develop new drug route of paclitaxel.
PartⅠProtective effect of dexamethasone on apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel
Objective To observe the effects of dexamethasone on apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel.Methods Human ovarian cancer cell line SKOV-3 was pretreated with dexamethasone at different concentrations for 24 hours,then was treated with Paclitaxel at different concentrations for 24 hours.MTT assay was used to examine the cell proliferation and the growth inhibition of SKOV-3 cell after treatments with dexamethasone and paclitaxel.The cell apoptotic rate of human ovarian cancer cell line SKOV-3 induced by paclitaxel in the presence or absence of dexamethasone was detected by TUNEL assay.The change of cell cycle and percentage of apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel in the presence or absence of dexamethasone was measured by PI-staining,and then analyzed by FCM.Results Paclitaxel can inhibit the cell proliferation of human ovarian cancer cell line SKOV-3 and was relative with the concentration.It was revealed that 0.001 uM～luM dexamethasone can protected differently the inhibition of human ovarian cancer cell line SKOV-3 proliferation induced by Paclitaxel.TUNEL and DAB staining assay showed that there was rarely apoptotic cells in control group,but there were many apoptotic cells with DAB-stained buffy nuclers,karyopycnosis or chromatin aggregation in human ovarian cancer cell line SKOV-3 induced by paclitaxel in the presence or absence of dexamethasone.The apoptotic rate was 3.5±0.25%and 4.0±0.26%in control group and Dex group with no difference between each other.The apoptotic rate was 11.7±1.72% and 30.8±1.15%in paclitaxel in the presence or absence of dexamethasone group,with significant difference between each other(p＜0.01).The apoptosis percentage of human ovarian cancer cell line SKOV-3 induced by paclitaxel and pretreated with dexamethasone measured by PI-staining was 5.55±0.53%,which was less than the apoptosis percentage 13.90±1.62%treated only with Paclitaxel(p＜0.01).The percentage of cell arrested by PTX in the G2/M phase was no significant difference in paclitaxel in the presence or absence of dexamethasone group(p＞0.05).Conclusion Dexamethasone can protected differently the inhibition of human ovarian cancer cell line SKOV-3 proliferation induced by paclitaxel and was relative with the concentration of dexamethasone.Dexamethasone can inhibit apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel without affecting the ability of paclitaxel to induce mitotic division arrest in the G2/M phase.
PartⅡPossible mechanisms of dexamethasone inhibit apoptosis of human ovarian cancer cell line SKOV-3 induced by Paclitaxel
Objective To investigate the possible mechanisms of dexamethasone inhibiting apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel.The experiment will settle ground work for the further study in vivo.Methods The expression levels of Survivin,Bcl-2,Bcl-X_L mRNA were determined by semi- quantiative RT-PCR after cells were treated by different methods.Western blot analysis was used to detect the expression levels of Bcl-X_L anti-apoptosis protain and activity of Caspase-3.Results The expression of Bcl-X_L,Survivin mRNA treated with dexamethasoneprior to paclitaxel were higher than treated only with paclitaxel(p＜0.01).The expression of Bcl-2 mRNA treated with dexamethasone prior to paclitaxelwas nearly same compared with treated only with paclitaxel(p＞0.05).The expression of Bcl-X_L protain in dexamethasone group is higher than control group(p＜0.01).The expression of Bcl-X_L protain treated with dexamethasone prior to paclitaxel was higher than treated only with paclitaxel(p＜0.01).The expression of Cleaved caspase-3 protain treated treated with dexamethasone prior to paclitaxel was lower than treated only with Paclitaxel(p＜0.01).Conclusion Pretreatment with dexamethasone can inhibit the paclitaxel -induced apoptosis of human ovarian cancer cell line SKOV-3.The possibbe mechanism is down- regulation of caspase-3 activity by Bcl-X_L,Survivin anti- apoptosis pathways.
PartⅢDexamethasone intereferes with therapeutic efficacy of paclitaxel against human ovarian cancer cell line SKOV-3 xenograft tumors
Objective We performed in vivo experiments through development of human ovarian cancer cell line SKOV-3 xenograft tumor models.We evaluate the potential effect of dexamethasone on the antitumor activity of paclitaxel in ovarian cancer cell line SKOV-3 xenograft tumors and analyze the mechanism furtherly.Methods We firstly developed the model of human ovarian cancer cell line SKOV-3 xenograft tumors,then mice were randomly divided into 4 groups(10 mice per group) and treated with various regimens on day 0(1) Control;(2) Dexamethasone alone at 1 mg/kg,ip;(3) Combination of dexamethasone and paclitaxel,in which dexamethasone was administered 12 h before paclitaxel treatment;(4) Paclitaxel alone at 20 mg/kg,iv.The same treatment regimens were repeated every 3 days for a total of 6 cycles.We observed the growth of human ovarian cancer cell line SKOV-3 xenograft tumors and drew the curve of xenograft tumors.After the mice were killed,the tumors were removed and their weights were measured.The inhibition rate of xenograft tumors growth was calculate.Immunohistochemistry assay the expression of Bcl-X_L,Cleaved caspase-3 protain and proliferation marker Ki-67 of human ovarian cancer cell line SKOV-3 xenograft tumors after 6 cycles of treatments.Under the microscope and transmission electric micro- scope,we observed the tissue morphous and ultramicrostructure.Results Nude mice bearing SKOV-3 xenograft tumors were treated with paclitaxel with pretreatment of dexamethasone,the xenograft tumors volumes were bigger than those in mice treated with paclitaxel alone(p＜0.01).The weight of xenograft tumors at the end of experiments for treated with paclitaxel with or without dexamethasone were 0.79±0.09g and 0.50±0.08g,respectively.The weight of xenograft tumors treated with paclitaxel with dexamethasone was more than treated with paclitaxel without dexamethasone.The inhibitory rate of paclitaxel alone was 65.28%.However,when the mice was pretreatment with dexamethasone,the IR of paclitaxel on SKOV-3 xenograft tumors dropped to 45.14%,which was 18-25%less than those in mice treated with paclitaxel alone.SKOV-3 xenograft tumors stained with HE,most xenograft tumor cells after the treatment of paclitaxel alone were found to become much larger,and the cellularity was reduced significantly when compared with that in any other groups.In addition,the SKOV-3 xenograft tumor cells exhibited typical apoptotic characteristics.In the group treated with combination of dexamethasone and paclitaxel,there were also many xenograft tumor cells exhibiting vacuolization and apoptotis features,but less than that in the group treated with paclitaxel alone.It was showed by electronic microscope that karyopycnosis or chromatin aggregation was more in the group treated with paclitaxel alone than in the group administered with dexamethasone prior to paclitaxel.The immunochemical results suggested that the expression of proliferation marker Ki-67 and Bcl-X_L protain in the group administered with dexamethasone prior to paclitaxel was significantly higher when compared with that in the group treated with paclitaxel alone(p＜0.0125).The expression of Cleaved caspase-3 protain in the group administered with dexamethasone prior to paclitaxel was significantly lower when compared with that in the group treated with paclitaxel alone(p＜0.0125).Conclusion Pretreatment with dexamethasone significantly interfered with the therapeutic activity of paclitaxe in human ovarian cancer cell line SKOV-3 xenograft tumors in vivo.Dexamethasone can inhibit paclitaxel-induced apoptosis in human ovarian cancer cell line SKOV-3 xenograft tumors in vivo.The possibbe mechanism is down-regulation of caspase-3 activity by up-regulation of Bcl-X_L anti- apoptosis pathways.
第一部分地塞米松对紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的保护作用
目的探讨地塞米松(Dex)对紫杉醇(PTX)抑制人卵巢癌细胞株SKOV-3细胞增殖及诱导SKOV-3细胞凋亡的影响。
方法(一)MTT法测定细胞增殖
1、用含不同浓度紫杉醇(10 nM、20 nM、50 nM、100nM)的培养液培养SKOV-3细胞24小时,测定紫杉醇对SKOV-3细胞增殖的影响。
2、用不同浓度地塞米松(0、0.001 uM、0.01 uM、0.1 uM、1uM)对SKOV-3细胞进行预处理24h后,每组中分别再用含不同浓度的紫杉醇(0、10 nM、20 nM、50 nM、100nM)培养液培养细胞24h,测定不同浓度的地塞米松对不同浓度的紫杉醇进行预处理后对SKOV-3细胞增殖的影响。
(二)TUNEL联合DAB染色从形态学观察地塞米松对紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的影响。
(三)PI单染法测定地塞米松对紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡及细胞周期的影响。
结果(一)PTX能够抑制人卵巢癌细胞株SKOV-3细胞增殖,且与PTX的浓度有关,浓度越高,抑制率越大。
(二)0.001～1uM浓度范围内地塞米松对紫杉醇抑制人卵巢癌细胞株SKOV-3细胞增殖有不同程度的保护作用。
(三)TUNEL法联合DAB染色进行形态学观察,对照组中极少见到凋亡细胞,PTX组出现大量DAB染的胞核呈棕黄色的凋亡细胞,表现为核固缩,染色质边聚,凝集成块,并可见散在棕色的凋亡小体。但预先用地塞米松进行处理后再用PTX处理组出现凋亡细胞较单用紫杉醇明显减少。凋亡指数(AI)在对照组和Dex组分别为3.5±0.25%和4.0±0.26%两组间无差异,在Dex+PTX组与PTX组为11.7±1.72%和30.8±1.15%,两组与对照组比较差异显著(P＜0.01),且Dex+PTX组与PTX组比较,Dex+PTX组凋亡指数降低,有明显差异(P＜0.01)。
(四)PI单染检测细胞凋亡率表明地塞米松进行预处理后再用紫杉醇组细胞凋亡率为5.55±0.53%较单用紫杉醇组细胞凋亡率13.90±1.62%明显降低(P＜0.01),而且在地塞米松拮抗紫杉醇诱导SKOV-3细胞凋亡中,用地塞米松预处理后再用紫杉醇组与单用紫杉醇组比较,细胞周期中G2/M期无明显差异(P＞0.05)。
结论(一)地塞米松对紫杉醇抑制人卵巢癌细胞株SKOV-3细胞增殖有保护作用,且与地塞米松的给药浓度有关。
(二)地塞米松能拮抗紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡,但与细胞周期中G2/M期停滞无关。
第二部分地塞米松拮抗紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的可能机制
目的从IAP家族中抗凋亡基因Survivin和Bcl-2家族中抗凋亡基因Bcl-2、Bcl-X_L两条通路,探讨地塞米松拮抗紫杉醇诱导人卵巢癌细胞株SKOV-3细胞凋亡的可能机制,并为下一步的动物实验奠定基础。
方法将细胞用不同药物处理后,用半定量RT—PCR检测凋亡相关基因Bcl-2、Bcl-X_L and Survivin mRNA的表达。Western blot检测Bcl-X_L和末端半胱氨酸蛋白酶Cleaved-caspase-3蛋白的表达。
结果(一)用地塞米松进行预处理后再用紫杉醇组(Dex+PTX组)与单用紫杉醇组(PTX组)比较,Dex+PTX组Bcl-X_L mRNA、Survivin mRNA的表达明显高于PTX组(P＜0.01)。
(二)Bcl-2蛋白家族成员Bcl-2 mRNA的表达:Dex组和Dex+PTX组Bcl-2蛋白家族成员Bcl-2 mRNA的表达较对照组无差异(P＞0.05),Dex+PTX组与PTX组之间比较也无差异(P＞0.05)。
(三)Bcl-X_L蛋白水平表达:Dex组较对照组升高(p＜0.01),而且用地塞米松进行预处理后再用紫杉醇组(Dex+PTX组)与单用紫杉醇组(PTX组)比较,Dex+PTX组Bcl-X_L蛋白表达明显高于PTX组(P＜0.01)。
(四)Cleaved caspase-3蛋白水平表达:Dex组和Dex+PTX组较对照组明显降低(p＜0.01),而且用地塞米松进行预处理后再用紫杉醇组(Dex+PTX组)与单用紫杉醇组(PTX组)比较,Dex+PTX组Cleaved caspase-3蛋白表达明显低于PTX组(P＜0.01)。
结论地塞米松对紫杉醇的抗凋亡作用可能通过上调IAP家族中Survivin和Bcl-2家族中Bcl-X_L抗凋亡基因的表达,下调caspase3活性,从而抑制人卵巢细胞株SKOV-3细胞凋亡。
第三部分地塞米松在人卵巢癌细胞株SKOV-3裸鼠移植瘤中对紫杉醇抗肿瘤疗效的影响
目的通过建立人卵巢癌细胞株SKOV-3裸鼠移植瘤模型进行体内实验,评价地塞米松进行预处理后,对紫杉醇抗肿瘤作用的影响,并进一步分析其作用机理。
方法(一)建立人卵巢癌细胞株SKOV-3裸鼠移植瘤的模型。
(二)分组及给药:(1)对照组:生理盐水(含0.001%无水乙醇),腹腔内注射;(2)地塞米松组:1mg/kg,腹腔内注射;(3)紫杉醇组:20mg/kg,尾静脉注射;(4)地塞米松+紫杉醇组:在其它三组给药前12小时,预先给予地塞米松1mg/kg,腹腔内注射,然后给予紫杉醇20mg╱kg,尾静脉注射。三天一个疗程,共6个疗程。
(三)观察移植瘤的生长,绘制裸鼠移植瘤的生长曲线,实验结束称瘤体的重量,计算肿瘤生长抑制率。
(四)免疫组化分析:Bcl-X_L和Cleaved caspase-3蛋白的表达,细胞增殖标记物Ki-67的表达。
(五)光镜和透射电镜下观察组织形态和细胞超微结构改变。
结果(一)在紫杉醇对SKOV-3裸鼠移植治疗中,用地塞米松进行预处理后再用紫杉醇组,移植瘤的体积较单用紫杉醇组增大(P＜0.01)。
(二)治疗结束后称瘤重,Dex+PTX治疗组瘤重为0.79±0.09g,PTX组瘤重为0.50±0.08g,Dex+PTX组较PTX组瘤重升高(P＜0.01)。Dex+PTX组和PTX组抑制率分别为45.14%和65.28%,PTX组较Dex+PTX组抑制率大约增加18—25%。
(三)HE染色后,PTX治疗组绝大部分细胞变大,细胞质较其它组明显减少,细胞表现为空泡和凋亡特征。在Dex+PTX组中也有一些细胞表现为空泡和凋亡特征,但明显少于PTX组。电镜下Dex+PTX组和PTX组可见核固缩,染色质边聚,凝集成块等细胞凋亡征象,但Dex+PTX组中细胞凋亡征象少于PTX组。
(四)免疫组化结果表明,Dex+PTX组与PTX组相比,在Dex+PTX组中Ki-67细胞增殖标记物、Bcl-X_L蛋白表达升高,Cleaved caspase-3蛋白表达降低,有显著性差异,P＜0.0125。
结论(一)体内实验证实地塞米松能降低紫杉醇对人卵巢癌SKOV-3裸鼠移植瘤治疗效果。
(二)体内实验证实地塞米松能拮抗紫杉醇诱导的人卵巢癌SKOV-3裸鼠移植瘤细胞凋亡,可能通过上调Bcl-2家族中Bcl-X_L抗凋亡基因,下调Cleaved-caspase3的活性。
In recent years,the chemotherapy of paclitaxel combined cisplatin has been widely used in the treatment of ovarian cancer,particularly for advanced that could not be operated,drug-refractory and metastatic ovarian cancer.Dexamethasone was routinely used as a premedication in the clinical applicantion of paclitaxel to prevent hypersensitivity and nausea.However,recently studies discovered that dexamethasone could selectively inhibit paclitaxel-induced apoptosis in a number of human solid tumor cells.It can downregulate the immune response and contribute to tumour metastasis.Pretreatment with dexamethasone interfered with the therapeutic efficacy of Paclitaxel.How is the influence of dexamethasone on paclitaxel-induced apoptosis in ovarian cancer cells? If dexamethasone can inhibit paclitaxel-induced apoptosis in ovarian cancer cells and reduce the therapeutic efficacy of paclitaxel.Therefore,we performed in vitro experiments with human ovarian cancer SKOV-3 cell line to evaluate the effects and mechanisms of dexamethasone on human ovarian cancer cell apoptosis induced by paclitaxel and to explore the influence of dexamethasone on antitumor therapeutic efficacy of paclitaxel in vivo through development of animal models bearing ovarian xenograft tumor.This finding may have a potential implication on how to use correctly dexamethasone in the clinical practice and to develop new drug route of paclitaxel.
PartⅠProtective effect of dexamethasone on apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel
Objective To observe the effects of dexamethasone on apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel.Methods Human ovarian cancer cell line SKOV-3 was pretreated with dexamethasone at different concentrations for 24 hours,then was treated with Paclitaxel at different concentrations for 24 hours.MTT assay was used to examine the cell proliferation and the growth inhibition of SKOV-3 cell after treatments with dexamethasone and paclitaxel.The cell apoptotic rate of human ovarian cancer cell line SKOV-3 induced by paclitaxel in the presence or absence of dexamethasone was detected by TUNEL assay.The change of cell cycle and percentage of apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel in the presence or absence of dexamethasone was measured by PI-staining,and then analyzed by FCM.Results Paclitaxel can inhibit the cell proliferation of human ovarian cancer cell line SKOV-3 and was relative with the concentration.It was revealed that 0.001 uM～luM dexamethasone can protected differently the inhibition of human ovarian cancer cell line SKOV-3 proliferation induced by Paclitaxel.TUNEL and DAB staining assay showed that there was rarely apoptotic cells in control group,but there were many apoptotic cells with DAB-stained buffy nuclers,karyopycnosis or chromatin aggregation in human ovarian cancer cell line SKOV-3 induced by paclitaxel in the presence or absence of dexamethasone.The apoptotic rate was 3.5±0.25%and 4.0±0.26%in control group and Dex group with no difference between each other.The apoptotic rate was 11.7±1.72% and 30.8±1.15%in paclitaxel in the presence or absence of dexamethasone group,with significant difference between each other(p＜0.01).The apoptosis percentage of human ovarian cancer cell line SKOV-3 induced by paclitaxel and pretreated with dexamethasone measured by PI-staining was 5.55±0.53%,which was less than the apoptosis percentage 13.90±1.62%treated only with Paclitaxel(p＜0.01).The percentage of cell arrested by PTX in the G2/M phase was no significant difference in paclitaxel in the presence or absence of dexamethasone group(p＞0.05).Conclusion Dexamethasone can protected differently the inhibition of human ovarian cancer cell line SKOV-3 proliferation induced by paclitaxel and was relative with the concentration of dexamethasone.Dexamethasone can inhibit apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel without affecting the ability of paclitaxel to induce mitotic division arrest in the G2/M phase.
PartⅡPossible mechanisms of dexamethasone inhibit apoptosis of human ovarian cancer cell line SKOV-3 induced by Paclitaxel
Objective To investigate the possible mechanisms of dexamethasone inhibiting apoptosis of human ovarian cancer cell line SKOV-3 induced by paclitaxel.The experiment will settle ground work for the further study in vivo.Methods The expression levels of Survivin,Bcl-2,Bcl-X_L mRNA were determined by semi- quantiative RT-PCR after cells were treated by different methods.Western blot analysis was used to detect the expression levels of Bcl-X_L anti-apoptosis protain and activity of Caspase-3.Results The expression of Bcl-X_L,Survivin mRNA treated with dexamethasoneprior to paclitaxel were higher than treated only with paclitaxel(p＜0.01).The expression of Bcl-2 mRNA treated with dexamethasone prior to paclitaxelwas nearly same compared with treated only with paclitaxel(p＞0.05).The expression of Bcl-X_L protain in dexamethasone group is higher than control group(p＜0.01).The expression of Bcl-X_L protain treated with dexamethasone prior to paclitaxel was higher than treated only with paclitaxel(p＜0.01).The expression of Cleaved caspase-3 protain treated treated with dexamethasone prior to paclitaxel was lower than treated only with Paclitaxel(p＜0.01).Conclusion Pretreatment with dexamethasone can inhibit the paclitaxel -induced apoptosis of human ovarian cancer cell line SKOV-3.The possibbe mechanism is down- regulation of caspase-3 activity by Bcl-X_L,Survivin anti- apoptosis pathways.
PartⅢDexamethasone intereferes with therapeutic efficacy of paclitaxel against human ovarian cancer cell line SKOV-3 xenograft tumors
Objective We performed in vivo experiments through development of human ovarian cancer cell line SKOV-3 xenograft tumor models.We evaluate the potential effect of dexamethasone on the antitumor activity of paclitaxel in ovarian cancer cell line SKOV-3 xenograft tumors and analyze the mechanism furtherly.Methods We firstly developed the model of human ovarian cancer cell line SKOV-3 xenograft tumors,then mice were randomly divided into 4 groups(10 mice per group) and treated with various regimens on day 0(1) Control;(2) Dexamethasone alone at 1 mg/kg,ip;(3) Combination of dexamethasone and paclitaxel,in which dexamethasone was administered 12 h before paclitaxel treatment;(4) Paclitaxel alone at 20 mg/kg,iv.The same treatment regimens were repeated every 3 days for a total of 6 cycles.We observed the growth of human ovarian cancer cell line SKOV-3 xenograft tumors and drew the curve of xenograft tumors.After the mice were killed,the tumors were removed and their weights were measured.The inhibition rate of xenograft tumors growth was calculate.Immunohistochemistry assay the expression of Bcl-X_L,Cleaved caspase-3 protain and proliferation marker Ki-67 of human ovarian cancer cell line SKOV-3 xenograft tumors after 6 cycles of treatments.Under the microscope and transmission electric micro- scope,we observed the tissue morphous and ultramicrostructure.Results Nude mice bearing SKOV-3 xenograft tumors were treated with paclitaxel with pretreatment of dexamethasone,the xenograft tumors volumes were bigger than those in mice treated with paclitaxel alone(p＜0.01).The weight of xenograft tumors at the end of experiments for treated with paclitaxel with or without dexamethasone were 0.79±0.09g and 0.50±0.08g,respectively.The weight of xenograft tumors treated with paclitaxel with dexamethasone was more than treated with paclitaxel without dexamethasone.The inhibitory rate of paclitaxel alone was 65.28%.However,when the mice was pretreatment with dexamethasone,the IR of paclitaxel on SKOV-3 xenograft tumors dropped to 45.14%,which was 18-25%less than those in mice treated with paclitaxel alone.SKOV-3 xenograft tumors stained with HE,most xenograft tumor cells after the treatment of paclitaxel alone were found to become much larger,and the cellularity was reduced significantly when compared with that in any other groups.In addition,the SKOV-3 xenograft tumor cells exhibited typical apoptotic characteristics.In the group treated with combination of dexamethasone and paclitaxel,there were also many xenograft tumor cells exhibiting vacuolization and apoptotis features,but less than that in the group treated with paclitaxel alone.It was showed by electronic microscope that karyopycnosis or chromatin aggregation was more in the group treated with paclitaxel alone than in the group administered with dexamethasone prior to paclitaxel.The immunochemical results suggested that the expression of proliferation marker Ki-67 and Bcl-X_L protain in the group administered with dexamethasone prior to paclitaxel was significantly higher when compared with that in the group treated with paclitaxel alone(p＜0.0125).The expression of Cleaved caspase-3 protain in the group administered with dexamethasone prior to paclitaxel was significantly lower when compared with that in the group treated with paclitaxel alone(p＜0.0125).Conclusion Pretreatment with dexamethasone significantly interfered with the therapeutic activity of paclitaxe in human ovarian cancer cell line SKOV-3 xenograft tumors in vivo.Dexamethasone can inhibit paclitaxel-induced apoptosis in human ovarian cancer cell line SKOV-3 xenograft tumors in vivo.The possibbe mechanism is down-regulation of caspase-3 activity by up-regulation of Bcl-X_L anti- apoptosis pathways.
引文
[1] Rutz HP, Herr I. Glucocorticoid administration in antiemetic therapy: is it safe? Cancer,2005,103: 2696
[2] Gassier N, Zhang C, Schnabel PA, et al. Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer, 2005,92: 1084—88
[3] Zhang C, Kolb A, Buchler P, et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts, and established cell lines of pancreatic cancer. BMCancer, 2006, 6: 61
[4] Ingrid Herr, Jesco Pfitzenmaier .Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases.Lancet Oncol, 2006, 7: 425-30
[5] Wu w,Pew T,Zou M,Pang D,ConzenSD.Glucocorticoid receptor-induced MAPK phosphatase-1 expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.J Biol Chem, 2005,280: 4117-24
[6] Herr I, Ucur E, Herzer K, et al. Glucocorticoid co-treatment induces apoptosis resistance toward cancer therapy in carcinomas.Cancer Res, 2003, 63: 3112-20
[7] Fan W, Everett ET, Tang C, Cooper T, Fang Q, Bhalla K and Norris JS, Glucocorticoid-mediated inhibition of paclitaxelinduced apoptosis in leiomyosarcoma cells. Cell Pharmacol, 1994,1:205-212
[8] Weimin Fan,Meihua Sui and Yi Huang.Glucocoticoids selectively inhibit paclitaxel-induced apoptosis:mechanisms and its clinical impact.Current Medicinal Chemistry, 2004,11:403-411
[9] Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol, 2002, 189:1-9
[10] Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein down regulation in MCF-7 cells. Br J Pharmacol, 2001, 133:467-76
[11] Buchmann A, Willy C, Buenemann CL, Stroh C, Schmiechen A, Schwarz M. Inhibition of transforming growth factor beta1-induced hepatoma cell apoptosis by liver tumor promoters:Characterization of primary signaling events and effects on CPP32-like caspaseactivity. Cell Death Differ, 1999, 6:190-200
[12] Yamamoto M, Fukuda K, Miura N, Suzuki R, Kido T, Komatsu Y. Inhibition by Dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: A possible association with Bcl-X_L induction. Hepatology ,1998, 27:959-66
[13] Gascoyne DM, Kypta RM, Vivanco MM. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-X_L. J Biol Chem, 2003,278:18022-9
[14] Hammer S, Sauer B, Spika I, Schraut C, Kleuser B, Schafer-Korting M. Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1- phosphate formation. J Cell Biochem, 2004,91:840-51
[15] Baumann S, Dostert A, Novac N, Bauer A, Schmid W, Fas SC, Krueger A, Heinzel T,Kirchhoff S, Schutz G, Krammer PH. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood, 2005,106:617-25
[16] Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, Burn TC, Allegretto EA. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology, 2002, 143:3866-74
[17] Yerramasetti R, Gollapudi S, Gupta S. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol, 2002,22:37-47
[18] Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol, 1995, 131:1095-103
[19] Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: Proteinase-independent and — dependent pathways. Development, 1996, 122:181-93
[20] Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res, 2000, 60:867-72
[21] Furth PA. Introduction: Mammary gland involution and apoptosis of mammary epithelialcells. J Mammary Gland Biol Neoplasia ,1999, 4:123-7
[22] Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem, 2001,276:16649-54
[23] Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res ,2004, 64:1757-64
[24] von Haefen C. Wieder T, Essman n F, et al. Paclitaxel induced apoptosis in BJAB cells proceeds via a death receptor independent,caspases-3 driven mitochondrial amplification loop[J]. Oncogene, 2003,22(15):2236-2247
[25] Han D ,Denison MS,Tachibana H ,Yamada K .Efects of estrogenic compounds on immunoglobulin production by mouse splenocytes.Biol Pharm Bull ,2002,25 (10): 1263-7
[26] Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia [J]. J Am Chem Soc, 1971,93 (9):2325-2327
[27] Tiefenthaler M, Amberger A, Bacher N,et al. Increased lactate production follows loss of mitochondrial membrane potential during apoptosis of human leukaemia cells[J].Br J Haematol,2001,114(3):574-580
[28]Morita K,Ishimura K,Tsuruo Y,et al.Dexamethasone enhances serum deprivation-induced necrotic death of rat C6 glioma cells through activation of glucocorticoid receptors.Brain Res,1999,816:309-316
[29]Tsai LC,Hung MW,Chang GC,et al.Apoptosis induced by the sodium butyrate in human gastric cancer TMK-1 cells.Anticancer Res,2000,20:2441-2448
[30]Karlan BY,Jones J,Slamon DJ,et al.Glucocorticoids stabilize HER-2 / neu messenger RNA in human epithelial ovarian carcinoma cells.Gynecol Oncol,1994,53:70-77
[31]Ferrandina G,Scambia G,Benedetti-Panici P,et al.Effects of Dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian csncer cells.Mol Cell Endocrinol,1992,83:183-193
[32]Braunschweiger PG,Tillg HL,Schiffer LM,et al.Correlation between GR content and the antiproliferative effect of Dexamethasome in experimental solid tumors.Cancer Res,1983,43:4757-4761
[33]卢建,张金山,牟瀚舟等.糖皮质激素对人卵巢癌细胞系增殖的抑制作[J].中华妇产科杂志,1996,31(3):183
[34]Widmann C,Gibson S,Jarpe MB,et al.Mitogen-activated protein kinase:conservation of a three-kinase module from yeast to human[J].Physiol Rev,1999,79(1):143-180
[35]徐明娟,宋万年等.糖皮质激素对人卵巢癌细胞系(3AO)的诱导分化作用[J].上海医学,2003,26(4):265-267
[36]Scheibe R J,Moeller-Runge I,Mueller WH.Retinoic acid induces the expression of alkaline phosphatase in P 19 teratocarcinoma cells.J Biol Chem,1991,266:21300-21305
[37]Karlan BY,Amin W,Casper SE,et al.Hormonal regulation of CA125 tumor marker expresaion in human ovarian carcinoma cells:inhibition by glucocorticoids.CAlncer Res,1988,48:3502-3506
[38]高洪泉,王英,郑海兴.苦参素诱导卵巢癌H089lO细胞凋亡[J].中医药学报,2004,32(6):10-11
[39]Eastman A.Activation of programmed cell death by anticancer agents:cisplatin as a model system.Cancer cells(cold spring Harbor),1990,2:275-278
[40]Hickman JA.Apoptosis and chemotherapy resistanc.EurJ Cancer,1996,32:921-926
[41]Lane DPA.Death in the life of P53.Nature(London),1993,362:786-788
[42]Baima B,Sticherling M.Apoptosis in different cutaneous manifestation of lupus erythematosus.Br J Dermatol,2001,144:958-966
[43]左连富主编.流式细胞术与生物医学.第一版.辽宁科学技术出版社,1996:8-10
[44] Li Elcma, Heikki Joensu, Jarmo Kucma, et al. Squamous cell Carcinoma is highly sensitive to taxel, a possible new radiation sensitizer[J].Acta Oldaryngal(Stockh), 1995, 115:340-344
[45] FAN W, SCHANDL CA, CHENG JS,et al. Glucocorticoids modulate paclitaxel cytotoxicity in human solid tumor cell[J]. Cell Pharmacol, 1996,3:343-348
[46] Medema JP, Scafidi C, Kischkel FC,et al .FLICE is activated by association with the CD95 death-inducing signaling complex(DISC). EMBO J ,1997, 16:2794 —2804
[47] Cryns V ,Yuan J .Protease to die for.Genes & Dev,1998, 12:1551 — 1570
[48] Villa P, Kaufmann SH, Earnshaw WC. Caspase and Caspase inhibitors.TIBS,1997;22:388-393
[49] Alnemri ES, Livingston DJ, Nicholson DW, et al. HumanI CE/CED-3 protease nomenclature. Cell, 1996,87:171
[50] Chang LC,Madsen SA,Toelboell T,Weber PS,Burton JL. Effects of glucocortico -ids on Fas gene expression in bovine blood neutrophils.J Endocrinol, 2004,183 (3): 569-83
[51] Takayama S, Sato T, Krajewski S, et al. Cloning and Functional analysis of BAG-l:a novel Bcl-2-binding protein With anti-cell death activity. Cell, 1995, 80:279-284
[52] Hanada M, Aime-Sempe C, Sato T,et al.Structure-function Analysis of Bcl-2 protein.J biol Chem, 1996,270:11962-11970
[53] Herod J, Eliopoulos AC, Warwick J, et al.The prognostic significance of bcl-2 and p53 expressions in ovarian carcinoma.Cancer Res, 1996,56:2178
[54] Pamela W, Peter G, Barbara W. Bcl-XL and Bax mediated regulation of apoptosis of human neutrophils via Caspase-3. Blood, 1999,93:3106
[55] Ambrosini G, Adida C, Altieri DCA novel anti-apoptosis gene,Survivin, expressed in cancer and lymphoma.Nat Med, 1997,3(8):917-921
[56] Adida C, Croty PL, Mcurathl, et al. Developmentally regulated expression of the novel cancer Anti-apoptosis gene Survivinin human and mouse diferentiation.Am J Pathol,1998,152(1):43
[57] Altieri DC, Marchisio PC and Marchisio C.Survivin apoptosis: an interloper between cell death and cell proliferation in cancer.lab Invest, 1999, 79(11): 1327-1333
[58] Newton K, Harris AW, Bath ML, et al. A dominant interfering mutant of FADD / MORTI enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J, 1998,17(3):706-718
[59] Salveson GS and Dixit VM. Caspases:intracellular signaling by proteolysis.Cell, 1997, 91(4): 443-446
[60] Nicholson DW and Thornberry N A. Caspases:killer proteases.Trends BiolSci, 1997, 22:299-306
[61] Suzuki A, Ito T, Kawano H ,et al .Survivin initiates procaspase3 /p21 Complex formation as a result of interaction with dk4 to resist Fas-mediated cell death.Oncogene,2000,19(10):1346-1353
[62]Conway EM,Poilefeyt S,Steiner-Mosonyi M,et al.Deficieroy of survivin in transgenic mice exacerbrates Fas-induced apoptosis via mitochondrial pathways[J].Gastroenterology,2002,123:619
[63]Du CY,Fa ng M,Li YC,et al.Smac,a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.Cell,2000,102(1):33-42
[64]Shin Sung B J,Cho YS.An anti-apoptotic protein human Survivin is a direct inihibitor of caspase-3and caspase-7[J].Biochemistry,2001,40:1117-1123
[65]Shi Y.Survivn structure:crystal unclear[J].Nat Structure Biol,2000,7:620
[66]Guo F,Nimmanapalli R,Paranawithhana S,et al.Ectopic overpression of second mitochondria-derived activator of caspases(Same/DIABLO)or cotreatment with N-terminus of Smae/DIABLO peptide potentiates epothilone B derivative-(BSM247550)and Ape-2L / TRALI-induced apoptosis[J].Blood,2002,99:3419
[67]AI Rabia MW,Blaylock MG,Sexton DW,Walsh GM,et al.Membrane receptor--mediated apoptosis and caspase activation in the diferentiated EoL-1 eosinophilic cell line.J Leukoc Biol,2004 Jun,75(6):1045-55
[68]Min DY,Lee YA,Ryu JS,Ahn MH,Chung YB,Sim S,Shin MH Caspase3 mediated apoptosis of human eosinophils by the tissue-invading helminth paragonimus westermani.Int Arch Allergy Immunol.2004 Apr,133(4):357-64.Epub 2004 Mar17
[69]Horvathova M.Human eosinophils as potent inflammatory cells and their apoptosis.Bratisl Lek Listy,2004,105(10-11):359-61
[70]李文锦,钱利年,吕文英.人卵巢上皮性癌裸鼠皮下移植瘤模型和腹水瘤模型的建立[J].中华妇产科杂志,1993,28(1):38
[71]孙慧,战忠利,黄建英,等.人卵巢癌裸鼠移植瘤模型的建立及生物学特性的实验应用研究[J].中国肿瘤临床,1994,2l(10):786
[72]Zhu X,Sui M,Fan W.Invitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel[J].Anticancer Res,2005,25(3B):1953-62
[73]Vakkala M,Kahols K,Lakari E,et al.Inducible nitric oxide synthase expression,apoptosis and angiogenesis in in situ and invasive breast carcinomas[J].Clin Cancer Res,2000,6(6):2408-2416
[74]MeGuire WP,Hoskins W J,Brady MF,et al.Cyelophosphamide compared with paelitaxel and cisplatin in patients with stage HI and Ⅳ ovarian cancer[J].N Engl J Med,1996,334(1):1-6
[75]Piccart M J,Bertelsen K,James K,et al.Randomized intergroup trial of cisplatin-paelitaxel versus cisplatin-cyelophosphamide in women with advanced epithelial ovarian cancer:three-year results[J].Nat Cancer Inst,2002,92:699-708
[76]The ICON and AGO Collaborators.Paelitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trial[J].Lancet,2003,361(9375):2099-2106
[77]Rygaard J,Povlsen CO.Heterotransplantation of a human malignant tumour to"Nude"mice[J].Acta Pathol Microbiol Stand,1969,77(4):758
[78]陈爱平,王和,彭芝兰等.人卵巢癌移植瘤和腹水瘤模型的建立及形态学观察[J].肿瘤,2001,21(2):82
[79]Malik ST,East N,Bomschi D,et al.Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models:comparison with the effects of tumour necrosis factor[J].Br J Cancer,1992,65(5):661
[80]岳静,李静,刑辉等.二种人卵巢癌动物模型的生物学特性比较[J].现代妇产科进展,2002,11(5):334
[81]张长英,成文彩.人卵巢癌裸鼠皮下移植瘤模型的建立[J].武汉科技大学学报(自然科学版),2001,24(1):99
[82]Gerdes J,Schwab U,Lemke H,Stein H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.Int J Cancer,1983,31(1):13-20
[83]Gerdes J,Lemke H,Baisch H,Wacker HH,Schwab U,Stein H.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.J Immunol,1984,133(4):1710-1715
[84]Cattoretti G,Becker MHG,Key G,Duchrow M,Schluter C,Galle J,et al.Monoclonal antibodies against recombinant parts of the Ki-67 antigen(MIBI and MIB3)detect proliferating cells in microwave-processed formalin-fixed paraffin sections.J Pathol,1992,168(4):357-363
[85]Betencourt MC,Bauer JJ,Sesterhenn LA,Mostofi FK,Mcleod DG,Moul JW.Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.J Uro1,1996,156(3):1064-1068
[86]Goff BA,Muntz HG,Greer BE,Tamimi HK,Gown AM,et al.Oncogene expression:long-term compared with short-term survival in patients with advanced epithelial ovarian cancer.Obstet Gynecol,1998,92(1):88-93
[87]Anttila M,Kosma VM,Ji H,Wei-Ling X,Puolakka J,Jubola M,et al.Clinical significance of a-catenin,collagen Ⅳ and Ki-67 expression in epithelial ovarian cancer.J Clin Onco1,1998;16(8): 2591-2600
[88]Krajewska M, Wang HG, Krajewski S, Zapata JM, Shabaik A, Gascoyne R, Reed JC. Immunohistochemical analysis of in vivo paterns of expression of CPP32(Caspase—3), a cell death protease. Cancer Res, 1997,57(8): 1605—1613
[1] Planey SL, Litwack G.Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun, 2000,279: 307-12
[2]Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology ,2002,60: 553-61
[3]Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet ,2002,360:1969-70
[4]Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol ,1996,14: 1756-64
[5]Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol ,1999,17: 2506-13
[6]Hench P, Kendall EC, Slocumb CH, Polley HF. The eff ect of a hormone of the adrenal cortex (17-Hydroxy-11-Dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. ProcStaff Meetings Mayo Clinic , 1949,24: 187-97
[7]Yeager MP, Guyre PM, Munck AU. Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol Scand ,2004,48: 799-813
[8]Neeck G. Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann NY Acad Sci ,2002,966: 28-38
[9]Frei E, Karon M, Levin RH, et al. The eff ectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood ,1965,26: 642-56
[10]Pearl JM, Nelson DP, Schwartz SM, et al. Glucocorticoids reduce ischemia-reperfusion-induced myocardial apoptosis in immature hearts. Ann Thorac Surg ,2002,74: 830-36
[11]Zurita M, Vaquero J, Oya S, Morales C. Effects of Dexamethasone on apoptosis-related cell death after spinal cord injury. J Neurosurg ,2002,96: 83-89
[12]Taylor SG. Hormonal modifi cation on the treatment of disseminated cancer of the breast. Am J Med, 1956,21:688-96
[13]Sui M, Chen F, Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 2005, published online Nov 8. DOI: 10.1002/ijc.21743
[14] Sherlock P, Hartmann WH. Adrenal steroids and the pattern of metastases of breast cancer. JAMA, 1962,181:313-17
[15]Iversen HG, Hjort GH. The infl uence of corticoid steroids on the frequency of spleen metastases in patients with breast cancer.Acta Pathol Microbiol Scand, 1958,44: 205-12
[16]Zhang C, Marme A, Wenger T, et al. Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int J Oncol,2006,2: 551-58
[17]Muenstedt K, Borces D, Bohlmann MK, et al. Glucocorticoid administration in antiemetic therapy. Cancer,2004,101: 1696-702
[18]Herr I, Ucur E, Herzer K, et al. Glucocorticoid co-treatment induces apoptosis resistance toward cancer therapy in carcinomas.Cancer Res,2003,63: 3112-20
[19]Postmus PE, Smit EF, Haaxma-Reiche H, et al, for the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Teniposide for brain metastases of small-cell lung cancer: a phase II study. J Clin Oncol, 1995,13: 660-65
[20]Zhang C, Kolb A, Mattern J, et al. Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy.Cancer Letters,2005,published online Dec 9. DOI:10.1016/ j. canlet. 2005.10.037
[21]Rasmuson T, Ljungberg B, Grankvist K, et al. Increased serum cortisol levels are associated with high tumour grade in patients with renal cell carcinoma. Acta Oncol,2001,40: 83-87
[22]Zhang C, Kolb A, Buchler P, et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections,xenografts, and established cell lines of pancreatic cancer.BMC Cancer,2006,6: 61
[23]Sorensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst,2004,96: 709-11
[24] Frankfurt O, Rosen ST. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol,2004,16: 553-63
[25]Haid M. Steroid antiemesis may be harmful. N Engl J Med ,1981,304: 1237
[26]Zhang C, Mattern J, Haferkamp A, et al. Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther,2006,5: 59-64
[27]Fidler IJ, Gersten DM, Kripke ML. Infl uence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res,1979,39: 3816-21
[28]Gorelick E, Segal S, Feldman M. Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity. J Natl Cancer Inst, 1980,65:1257-64
[29]Seshadri M,Poduval TB,Sundaram K.Studies on metastases.I.Role of sensitization and immunosuppression.J Natl Cancer Inst,1979,63:1205-09
[30]张天泽.肿瘤学[M].天津科学技术出版社,1996,764-767
[31]鄂征.癌变机理研究[M].北京出版社,1999,304-315
[32]Gorelik E,Herberman RB.Role of natural killer(NK)cells in the control of tumor growt h and metastatic spread.Cancer Immunology:Innovative Approaches to Thempy.Boston,Mass:Martinus Nijhof,1986,151-176
[33]苏燎原,徐映东,耿勇志等.各淋巴细胞杀伤肿瘤细胞的初步研究[J].苏州医学院学报,1993,13(1):6-8
[34]Soygnr T,Beduk Y,Baltaci S,et al.The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using nooedjuvant M-VEC chemotherapy[J].BJU Int,1999,84(9):1069-1072
[35]张淑芬,牛立钢.应用枢复宁及胃复安控制化疗所致胃肠道反应的效果观察[J].实用肿瘤学杂志,1998,12(3):227-230
[36]郝勤岭.高剂量灭吐灵配合其他约物预防顺铂引起呕吐疗效观察[J].河南肿瘤学杂志,2000,13(5):337-338
[37]Boumpas DT,Chrousos GP,Wilder RL,et al.Glucocorticoid therapy for immune-mediated diseases:basic and clinicalcorrelates.Ann Intern Med,1993,119:1198-208
[38]von Knebel Doeberitz M,Koch S,Drzonek H,Zur Hausen H.Glucocorticoid hormones reduce the expression of major histocompatibility class I antigens on human epithelial cells.Eur J Immunol,1990,20:35-40
[39]Powell CB,Mutch DG,Kao MS,et al.Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic(NC) cell activity.Cancer,1990,65:466-72
[40]Collins JL,Patek PQ,Cohn M.Tumorigenicity and Iysis by natural killers.J Exp Med,1981,153:89-106
[1]Wani MC,Taylor HL,Wall ME,et al.Plant antitumor agents Ⅵ.The isolation and structure of taxol,a novel antileukemic and antitumor agent from Taxus brevifolia[J].J Am Chem Soc,1971,93(9):2325-2327
[2]AL-Sarrf M.Treatment of locally advanced head and neck cancer[J].C4wlcer Control,2002,9(5):387-399
[3]Panvichian R,Orth K,Day ML,et al.Paclitaxel-associated multi-minricmcleation is permitted by the inhibition of caspas sctivation:apotential early step in druy resistance[J].Cancer Res,1998,58(20):4667
[4]Li Elcma,Heikki Joensu,Jarmo Kucma,et al.Squamous cell Carcinoma is highly sensitive to taxel,a possible new radiation sensitizer[J].Acta Oldaryngal(Stockh),1995,115:340-344
[5]Roussel E,Belanger MM,Couet J.G2/Mblockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells:caveolin-1 as a marker of cytotoxicity[J].Anticancer Drugs,2004,15(10):961-967
[6]Salah-Eldin AE,Inoue S,Tsukamoto S,et al.An association of Bci-2 pheaphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment[J].Int J Cancer,2003,103(1):53-60
[7]Longguet M,Serduc R,Riva C.Implication of bax in apoptosis depends on microtubule network mobility[J].Int J Oncol,2004 25(2):309-317
[8]Stumm S,Meyer A,Lindner M,et al.Paclitaxel treatment of breat cancer cell lines modulates Fas /Fasl ligand expression and induces apoptosis which can be inhibited the CD4 receptor[J].Oncology,2004 66(2):101-111
[9]Weimin Fan,Meihua Sui and Yi Huang.Glucocoticoids selectively inhibit paclitaxel-induced apoptosis:mechanisms and its clinical impact.Current Medicinal Chemistry.2004,Feb;11(4),403-411
[10]McGuire WI,Rowinsky SK,Rosensndhein NB,et al.Taxol:aunigue antineoplastic agent with significannt activity inadvaneed ovarian epithelial neoplasms[J].Annintem Med,1989,111:273
[11]孙热,刘丽影,范魁生,等紫杉醇治疗中晚期恶性肿瘤[J],中国新药杂志,1996,5(4):252
[12]Andreasdu Bois,Handluck,Wemer Meier,et al.Carboplation plus paclutaxel as first line Chemotherapy in previously untreated advanced ovarian cancer[J].Semin Oncol,1997,24(11):28
[13]Shikawa H,Nakanishi TT,Nawa A,et al.3-hourin infusion of single-agent paclitaxel for recurrent ovarian cancer[J].Int J Clin Oncol,2001,6(3):128
[14]J Ghamande S,Lele S,Marchetti D,et al.Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer[J].Int J Gynecol Cancer,2003,13(2):142 147
[15]杨磊,樊红.紫杉类抗肿瘤药物的临床应用进展[J].中国医院用药评价与分析,2004,4(1):58
[16]苏卫,孙素华.以紫杉醇为主的联合化疗方案治疗转移性乳腺癌[J].临床肿瘤学杂志,2003,8(3):1861
[17]Henderson C,Berry DA,Demetri GD,et al.Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast caneer[J].J Clin Oncol,2003,21(6):9761
[18]陈良良,吴良村,谢长生,等.紫杉醇联合顺铂治疗Ⅲ-Ⅳ期非小细胞肺癌37例[J].实刚肿瘤学杂志,2004,18(1):31-32
[19]陈剑锋,郭文璇.紫杉醇、卡铂联合治疗非小细胞肺癌[J].河北医学,2003,9(4):308-310
[20]黄荣和,莫汉文.放射治疗合并紫杉醇治疗中晚期肺癌的临床疗效[J].重庆医学,2003,32(6):761-762
[21]Anon Scrip,1994(1880):20
[22]Forasfiere A A,Nerbera D,Taylor S G,et al.Monogr Nail Cancer Inst,1993:15-18
[23]孙明,陈一戎,王志平等.紫杉醇和维甲酸对前列腺癌PC一3细胞的作用.中华实验外科杂忠[J],2004,21(5):586-588
[24]Rowinsky EK,Burke PJ,Karp JE,et al.Phase 1 and pharmacodynamic study of taxol in refractory acute leukemias[J].Cancer Res,1989.49(16):4640-4647
[25]张湘茹,孙燕紫杉醇治疗非小细胞肺癌[J].中国新药杂志,1996,5(4):245-248
[26]Weiss RB,Donehower RC,Wreinik PH,et al.Hypersensitivity reactions from taxol[J].J Clin Oncol,1990,8(7):1263-1268
[27]Morita K,Ishimura K,Tsuruo Y,et al.Dexamethasone enhances serum deprivation-induced necrotic death of rat C6 glioma ceils through activation of glucocorticoid receptors.Brain Res,1999,816:309-16
[28]Tsai LC,Hung M W,Chang GC,et al.Apo ptosis induced by the sodium butyrate in human gastric cancer TM K-I ceils.Anticancer Res,2000,20:2441-2448
[29]Karlan BY,Jones J,Slam on DJ,et aI.Glucoconicoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.Gynecol Oncol,1994,53:70-77
[30]Ferrandina G,Scambia G,Benedetti Panici P,et al.Effects of Dexamethaso ne on the growth and epidermal growth factor receptor expresion of the OVCA 433 ovarian cancer ceils.Mol Cell Endocrinol,1992,83:183-193
[31]Braunschweiger PG,Ting HL,Schiffer LM.Correlation between GR content and the antiproliferative effect of Dexamethasone in experimental solid tumors.Cancer Res,1983,43:4757-4761
[32]McNally JG,Muller WG,Walker D,et al.The glucocorticoid receptor:rapid exchange with regulatory sites in living cells.Science,2000,287:1262-1265
[33]Wu w,Pew T,Zou M,Pang D,ConzenSD.Glucocorticoid receptor-induced MAPK phosphatase-1 expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.J Biol Chem 2005;280:4117-24
[34]Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol,2002,189:l-9
[35]Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J.Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein down regulation in MCF-7 cells.Br J Pharmacol, 2001,133:467-76
[36]Buchmann A, Willy C, Buenemann CL, Stroh C, Schmiechen A, Schwarz M. Inhibition of transforming growth factor beta1-induced hepatoma cell apoptosis by liver tumor promoters:Characterization of primary signaling events and effects on CPP32-like caspaseactivity. Cell Death Differ, 1999,6:190-200
[37]Yamamoto M, Fukuda K, Miura N, Suzuki R, Kido T, Komatsu Y. Inhibition by Dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: A possible association with Bcl-XL induction. Hepatology, 1998, 27:959-66.
[38]Gascoyne DM, Kypta RM, Vivanco MM. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-XL. J Biol Chem, 2003,278:18022-9
[39]Hammer S, Sauer B, Spika I, Schraut C, Kleuser B, Schafer-Korting M. Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1- phosphate formation. J Cell Biochem, 2004, 91:840-51
[40]Baumann S, Dostert A, Novac N, Bauer A, Schmid W, Fas SC, Krueger A, Heinzel T,Kirchhoff S, Schutz G, Krammer PH. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood, 2005, 106:617-25
[41]Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, Burn TC, Allegretto EA. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology, 2002, 143:3866-74
[42]Yerramasetti R, Gollapudi S, Gupta S. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol, 2002, 22:37-47
[43]Topper YJ, Freeman CS. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev, 1980, 60:1049-106
[44]Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol, 1995, 131:1095-103.
[45]Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: Proteinase-independent and dependent pathways. Development, 1996, 122:181-93
[46]Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res ,2000, 60:867-72
[47]Furth PA. Introduction: Mammary gland involution and apoptosis of mammary epithelialcells. J Mammary Gland Biol Neoplasia, 1999,4:123-7
[48]Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor- mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem, 2001,276:16649-54
[49]Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res, 2004, 64:1757-64
[50]Kobayashi T, Cohen P. Activation of serum- and glucocorticoid -regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositi dedependent protein kinase-1 (PDK1) and PDK2. Biochem J, 1999, 339:319-28
[51 ]Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M,Debatin KM. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res, 2003, 63: 3112-20
[52]Meihua Sui,Feng Chen, Zhi Chen and Weimin Fan Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int JCancer , 2006, 119: 712-717
[53]Pharm-Res, 2005 Apr, 22(4): 573-83
[2] Gassier N, Zhang C, Schnabel PA, et al. Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer, 2005,92: 1084—88
[3] Zhang C, Kolb A, Buchler P, et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts, and established cell lines of pancreatic cancer. BMCancer, 2006, 6: 61
[4] Ingrid Herr, Jesco Pfitzenmaier .Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases.Lancet Oncol, 2006, 7: 425-30
[5] Wu w,Pew T,Zou M,Pang D,ConzenSD.Glucocorticoid receptor-induced MAPK phosphatase-1 expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.J Biol Chem, 2005,280: 4117-24
[6] Herr I, Ucur E, Herzer K, et al. Glucocorticoid co-treatment induces apoptosis resistance toward cancer therapy in carcinomas.Cancer Res, 2003, 63: 3112-20
[7] Fan W, Everett ET, Tang C, Cooper T, Fang Q, Bhalla K and Norris JS, Glucocorticoid-mediated inhibition of paclitaxelinduced apoptosis in leiomyosarcoma cells. Cell Pharmacol, 1994,1:205-212
[8] Weimin Fan,Meihua Sui and Yi Huang.Glucocoticoids selectively inhibit paclitaxel-induced apoptosis:mechanisms and its clinical impact.Current Medicinal Chemistry, 2004,11:403-411
[9] Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol, 2002, 189:1-9
[10] Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein down regulation in MCF-7 cells. Br J Pharmacol, 2001, 133:467-76
[11] Buchmann A, Willy C, Buenemann CL, Stroh C, Schmiechen A, Schwarz M. Inhibition of transforming growth factor beta1-induced hepatoma cell apoptosis by liver tumor promoters:Characterization of primary signaling events and effects on CPP32-like caspaseactivity. Cell Death Differ, 1999, 6:190-200
[12] Yamamoto M, Fukuda K, Miura N, Suzuki R, Kido T, Komatsu Y. Inhibition by Dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: A possible association with Bcl-X_L induction. Hepatology ,1998, 27:959-66
[13] Gascoyne DM, Kypta RM, Vivanco MM. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-X_L. J Biol Chem, 2003,278:18022-9
[14] Hammer S, Sauer B, Spika I, Schraut C, Kleuser B, Schafer-Korting M. Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1- phosphate formation. J Cell Biochem, 2004,91:840-51
[15] Baumann S, Dostert A, Novac N, Bauer A, Schmid W, Fas SC, Krueger A, Heinzel T,Kirchhoff S, Schutz G, Krammer PH. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood, 2005,106:617-25
[16] Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, Burn TC, Allegretto EA. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology, 2002, 143:3866-74
[17] Yerramasetti R, Gollapudi S, Gupta S. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol, 2002,22:37-47
[18] Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol, 1995, 131:1095-103
[19] Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: Proteinase-independent and — dependent pathways. Development, 1996, 122:181-93
[20] Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res, 2000, 60:867-72
[21] Furth PA. Introduction: Mammary gland involution and apoptosis of mammary epithelialcells. J Mammary Gland Biol Neoplasia ,1999, 4:123-7
[22] Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem, 2001,276:16649-54
[23] Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res ,2004, 64:1757-64
[24] von Haefen C. Wieder T, Essman n F, et al. Paclitaxel induced apoptosis in BJAB cells proceeds via a death receptor independent,caspases-3 driven mitochondrial amplification loop[J]. Oncogene, 2003,22(15):2236-2247
[25] Han D ,Denison MS,Tachibana H ,Yamada K .Efects of estrogenic compounds on immunoglobulin production by mouse splenocytes.Biol Pharm Bull ,2002,25 (10): 1263-7
[26] Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia [J]. J Am Chem Soc, 1971,93 (9):2325-2327
[27] Tiefenthaler M, Amberger A, Bacher N,et al. Increased lactate production follows loss of mitochondrial membrane potential during apoptosis of human leukaemia cells[J].Br J Haematol,2001,114(3):574-580
[28]Morita K,Ishimura K,Tsuruo Y,et al.Dexamethasone enhances serum deprivation-induced necrotic death of rat C6 glioma cells through activation of glucocorticoid receptors.Brain Res,1999,816:309-316
[29]Tsai LC,Hung MW,Chang GC,et al.Apoptosis induced by the sodium butyrate in human gastric cancer TMK-1 cells.Anticancer Res,2000,20:2441-2448
[30]Karlan BY,Jones J,Slamon DJ,et al.Glucocorticoids stabilize HER-2 / neu messenger RNA in human epithelial ovarian carcinoma cells.Gynecol Oncol,1994,53:70-77
[31]Ferrandina G,Scambia G,Benedetti-Panici P,et al.Effects of Dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian csncer cells.Mol Cell Endocrinol,1992,83:183-193
[32]Braunschweiger PG,Tillg HL,Schiffer LM,et al.Correlation between GR content and the antiproliferative effect of Dexamethasome in experimental solid tumors.Cancer Res,1983,43:4757-4761
[33]卢建,张金山,牟瀚舟等.糖皮质激素对人卵巢癌细胞系增殖的抑制作[J].中华妇产科杂志,1996,31(3):183
[34]Widmann C,Gibson S,Jarpe MB,et al.Mitogen-activated protein kinase:conservation of a three-kinase module from yeast to human[J].Physiol Rev,1999,79(1):143-180
[35]徐明娟,宋万年等.糖皮质激素对人卵巢癌细胞系(3AO)的诱导分化作用[J].上海医学,2003,26(4):265-267
[36]Scheibe R J,Moeller-Runge I,Mueller WH.Retinoic acid induces the expression of alkaline phosphatase in P 19 teratocarcinoma cells.J Biol Chem,1991,266:21300-21305
[37]Karlan BY,Amin W,Casper SE,et al.Hormonal regulation of CA125 tumor marker expresaion in human ovarian carcinoma cells:inhibition by glucocorticoids.CAlncer Res,1988,48:3502-3506
[38]高洪泉,王英,郑海兴.苦参素诱导卵巢癌H089lO细胞凋亡[J].中医药学报,2004,32(6):10-11
[39]Eastman A.Activation of programmed cell death by anticancer agents:cisplatin as a model system.Cancer cells(cold spring Harbor),1990,2:275-278
[40]Hickman JA.Apoptosis and chemotherapy resistanc.EurJ Cancer,1996,32:921-926
[41]Lane DPA.Death in the life of P53.Nature(London),1993,362:786-788
[42]Baima B,Sticherling M.Apoptosis in different cutaneous manifestation of lupus erythematosus.Br J Dermatol,2001,144:958-966
[43]左连富主编.流式细胞术与生物医学.第一版.辽宁科学技术出版社,1996:8-10
[44] Li Elcma, Heikki Joensu, Jarmo Kucma, et al. Squamous cell Carcinoma is highly sensitive to taxel, a possible new radiation sensitizer[J].Acta Oldaryngal(Stockh), 1995, 115:340-344
[45] FAN W, SCHANDL CA, CHENG JS,et al. Glucocorticoids modulate paclitaxel cytotoxicity in human solid tumor cell[J]. Cell Pharmacol, 1996,3:343-348
[46] Medema JP, Scafidi C, Kischkel FC,et al .FLICE is activated by association with the CD95 death-inducing signaling complex(DISC). EMBO J ,1997, 16:2794 —2804
[47] Cryns V ,Yuan J .Protease to die for.Genes & Dev,1998, 12:1551 — 1570
[48] Villa P, Kaufmann SH, Earnshaw WC. Caspase and Caspase inhibitors.TIBS,1997;22:388-393
[49] Alnemri ES, Livingston DJ, Nicholson DW, et al. HumanI CE/CED-3 protease nomenclature. Cell, 1996,87:171
[50] Chang LC,Madsen SA,Toelboell T,Weber PS,Burton JL. Effects of glucocortico -ids on Fas gene expression in bovine blood neutrophils.J Endocrinol, 2004,183 (3): 569-83
[51] Takayama S, Sato T, Krajewski S, et al. Cloning and Functional analysis of BAG-l:a novel Bcl-2-binding protein With anti-cell death activity. Cell, 1995, 80:279-284
[52] Hanada M, Aime-Sempe C, Sato T,et al.Structure-function Analysis of Bcl-2 protein.J biol Chem, 1996,270:11962-11970
[53] Herod J, Eliopoulos AC, Warwick J, et al.The prognostic significance of bcl-2 and p53 expressions in ovarian carcinoma.Cancer Res, 1996,56:2178
[54] Pamela W, Peter G, Barbara W. Bcl-XL and Bax mediated regulation of apoptosis of human neutrophils via Caspase-3. Blood, 1999,93:3106
[55] Ambrosini G, Adida C, Altieri DCA novel anti-apoptosis gene,Survivin, expressed in cancer and lymphoma.Nat Med, 1997,3(8):917-921
[56] Adida C, Croty PL, Mcurathl, et al. Developmentally regulated expression of the novel cancer Anti-apoptosis gene Survivinin human and mouse diferentiation.Am J Pathol,1998,152(1):43
[57] Altieri DC, Marchisio PC and Marchisio C.Survivin apoptosis: an interloper between cell death and cell proliferation in cancer.lab Invest, 1999, 79(11): 1327-1333
[58] Newton K, Harris AW, Bath ML, et al. A dominant interfering mutant of FADD / MORTI enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J, 1998,17(3):706-718
[59] Salveson GS and Dixit VM. Caspases:intracellular signaling by proteolysis.Cell, 1997, 91(4): 443-446
[60] Nicholson DW and Thornberry N A. Caspases:killer proteases.Trends BiolSci, 1997, 22:299-306
[61] Suzuki A, Ito T, Kawano H ,et al .Survivin initiates procaspase3 /p21 Complex formation as a result of interaction with dk4 to resist Fas-mediated cell death.Oncogene,2000,19(10):1346-1353
[62]Conway EM,Poilefeyt S,Steiner-Mosonyi M,et al.Deficieroy of survivin in transgenic mice exacerbrates Fas-induced apoptosis via mitochondrial pathways[J].Gastroenterology,2002,123:619
[63]Du CY,Fa ng M,Li YC,et al.Smac,a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.Cell,2000,102(1):33-42
[64]Shin Sung B J,Cho YS.An anti-apoptotic protein human Survivin is a direct inihibitor of caspase-3and caspase-7[J].Biochemistry,2001,40:1117-1123
[65]Shi Y.Survivn structure:crystal unclear[J].Nat Structure Biol,2000,7:620
[66]Guo F,Nimmanapalli R,Paranawithhana S,et al.Ectopic overpression of second mitochondria-derived activator of caspases(Same/DIABLO)or cotreatment with N-terminus of Smae/DIABLO peptide potentiates epothilone B derivative-(BSM247550)and Ape-2L / TRALI-induced apoptosis[J].Blood,2002,99:3419
[67]AI Rabia MW,Blaylock MG,Sexton DW,Walsh GM,et al.Membrane receptor--mediated apoptosis and caspase activation in the diferentiated EoL-1 eosinophilic cell line.J Leukoc Biol,2004 Jun,75(6):1045-55
[68]Min DY,Lee YA,Ryu JS,Ahn MH,Chung YB,Sim S,Shin MH Caspase3 mediated apoptosis of human eosinophils by the tissue-invading helminth paragonimus westermani.Int Arch Allergy Immunol.2004 Apr,133(4):357-64.Epub 2004 Mar17
[69]Horvathova M.Human eosinophils as potent inflammatory cells and their apoptosis.Bratisl Lek Listy,2004,105(10-11):359-61
[70]李文锦,钱利年,吕文英.人卵巢上皮性癌裸鼠皮下移植瘤模型和腹水瘤模型的建立[J].中华妇产科杂志,1993,28(1):38
[71]孙慧,战忠利,黄建英,等.人卵巢癌裸鼠移植瘤模型的建立及生物学特性的实验应用研究[J].中国肿瘤临床,1994,2l(10):786
[72]Zhu X,Sui M,Fan W.Invitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel[J].Anticancer Res,2005,25(3B):1953-62
[73]Vakkala M,Kahols K,Lakari E,et al.Inducible nitric oxide synthase expression,apoptosis and angiogenesis in in situ and invasive breast carcinomas[J].Clin Cancer Res,2000,6(6):2408-2416
[74]MeGuire WP,Hoskins W J,Brady MF,et al.Cyelophosphamide compared with paelitaxel and cisplatin in patients with stage HI and Ⅳ ovarian cancer[J].N Engl J Med,1996,334(1):1-6
[75]Piccart M J,Bertelsen K,James K,et al.Randomized intergroup trial of cisplatin-paelitaxel versus cisplatin-cyelophosphamide in women with advanced epithelial ovarian cancer:three-year results[J].Nat Cancer Inst,2002,92:699-708
[76]The ICON and AGO Collaborators.Paelitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trial[J].Lancet,2003,361(9375):2099-2106
[77]Rygaard J,Povlsen CO.Heterotransplantation of a human malignant tumour to"Nude"mice[J].Acta Pathol Microbiol Stand,1969,77(4):758
[78]陈爱平,王和,彭芝兰等.人卵巢癌移植瘤和腹水瘤模型的建立及形态学观察[J].肿瘤,2001,21(2):82
[79]Malik ST,East N,Bomschi D,et al.Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models:comparison with the effects of tumour necrosis factor[J].Br J Cancer,1992,65(5):661
[80]岳静,李静,刑辉等.二种人卵巢癌动物模型的生物学特性比较[J].现代妇产科进展,2002,11(5):334
[81]张长英,成文彩.人卵巢癌裸鼠皮下移植瘤模型的建立[J].武汉科技大学学报(自然科学版),2001,24(1):99
[82]Gerdes J,Schwab U,Lemke H,Stein H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.Int J Cancer,1983,31(1):13-20
[83]Gerdes J,Lemke H,Baisch H,Wacker HH,Schwab U,Stein H.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.J Immunol,1984,133(4):1710-1715
[84]Cattoretti G,Becker MHG,Key G,Duchrow M,Schluter C,Galle J,et al.Monoclonal antibodies against recombinant parts of the Ki-67 antigen(MIBI and MIB3)detect proliferating cells in microwave-processed formalin-fixed paraffin sections.J Pathol,1992,168(4):357-363
[85]Betencourt MC,Bauer JJ,Sesterhenn LA,Mostofi FK,Mcleod DG,Moul JW.Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.J Uro1,1996,156(3):1064-1068
[86]Goff BA,Muntz HG,Greer BE,Tamimi HK,Gown AM,et al.Oncogene expression:long-term compared with short-term survival in patients with advanced epithelial ovarian cancer.Obstet Gynecol,1998,92(1):88-93
[87]Anttila M,Kosma VM,Ji H,Wei-Ling X,Puolakka J,Jubola M,et al.Clinical significance of a-catenin,collagen Ⅳ and Ki-67 expression in epithelial ovarian cancer.J Clin Onco1,1998;16(8): 2591-2600
[88]Krajewska M, Wang HG, Krajewski S, Zapata JM, Shabaik A, Gascoyne R, Reed JC. Immunohistochemical analysis of in vivo paterns of expression of CPP32(Caspase—3), a cell death protease. Cancer Res, 1997,57(8): 1605—1613
[1] Planey SL, Litwack G.Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun, 2000,279: 307-12
[2]Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology ,2002,60: 553-61
[3]Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet ,2002,360:1969-70
[4]Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol ,1996,14: 1756-64
[5]Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol ,1999,17: 2506-13
[6]Hench P, Kendall EC, Slocumb CH, Polley HF. The eff ect of a hormone of the adrenal cortex (17-Hydroxy-11-Dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. ProcStaff Meetings Mayo Clinic , 1949,24: 187-97
[7]Yeager MP, Guyre PM, Munck AU. Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol Scand ,2004,48: 799-813
[8]Neeck G. Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann NY Acad Sci ,2002,966: 28-38
[9]Frei E, Karon M, Levin RH, et al. The eff ectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood ,1965,26: 642-56
[10]Pearl JM, Nelson DP, Schwartz SM, et al. Glucocorticoids reduce ischemia-reperfusion-induced myocardial apoptosis in immature hearts. Ann Thorac Surg ,2002,74: 830-36
[11]Zurita M, Vaquero J, Oya S, Morales C. Effects of Dexamethasone on apoptosis-related cell death after spinal cord injury. J Neurosurg ,2002,96: 83-89
[12]Taylor SG. Hormonal modifi cation on the treatment of disseminated cancer of the breast. Am J Med, 1956,21:688-96
[13]Sui M, Chen F, Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 2005, published online Nov 8. DOI: 10.1002/ijc.21743
[14] Sherlock P, Hartmann WH. Adrenal steroids and the pattern of metastases of breast cancer. JAMA, 1962,181:313-17
[15]Iversen HG, Hjort GH. The infl uence of corticoid steroids on the frequency of spleen metastases in patients with breast cancer.Acta Pathol Microbiol Scand, 1958,44: 205-12
[16]Zhang C, Marme A, Wenger T, et al. Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int J Oncol,2006,2: 551-58
[17]Muenstedt K, Borces D, Bohlmann MK, et al. Glucocorticoid administration in antiemetic therapy. Cancer,2004,101: 1696-702
[18]Herr I, Ucur E, Herzer K, et al. Glucocorticoid co-treatment induces apoptosis resistance toward cancer therapy in carcinomas.Cancer Res,2003,63: 3112-20
[19]Postmus PE, Smit EF, Haaxma-Reiche H, et al, for the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Teniposide for brain metastases of small-cell lung cancer: a phase II study. J Clin Oncol, 1995,13: 660-65
[20]Zhang C, Kolb A, Mattern J, et al. Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy.Cancer Letters,2005,published online Dec 9. DOI:10.1016/ j. canlet. 2005.10.037
[21]Rasmuson T, Ljungberg B, Grankvist K, et al. Increased serum cortisol levels are associated with high tumour grade in patients with renal cell carcinoma. Acta Oncol,2001,40: 83-87
[22]Zhang C, Kolb A, Buchler P, et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections,xenografts, and established cell lines of pancreatic cancer.BMC Cancer,2006,6: 61
[23]Sorensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst,2004,96: 709-11
[24] Frankfurt O, Rosen ST. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol,2004,16: 553-63
[25]Haid M. Steroid antiemesis may be harmful. N Engl J Med ,1981,304: 1237
[26]Zhang C, Mattern J, Haferkamp A, et al. Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther,2006,5: 59-64
[27]Fidler IJ, Gersten DM, Kripke ML. Infl uence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res,1979,39: 3816-21
[28]Gorelick E, Segal S, Feldman M. Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity. J Natl Cancer Inst, 1980,65:1257-64
[29]Seshadri M,Poduval TB,Sundaram K.Studies on metastases.I.Role of sensitization and immunosuppression.J Natl Cancer Inst,1979,63:1205-09
[30]张天泽.肿瘤学[M].天津科学技术出版社,1996,764-767
[31]鄂征.癌变机理研究[M].北京出版社,1999,304-315
[32]Gorelik E,Herberman RB.Role of natural killer(NK)cells in the control of tumor growt h and metastatic spread.Cancer Immunology:Innovative Approaches to Thempy.Boston,Mass:Martinus Nijhof,1986,151-176
[33]苏燎原,徐映东,耿勇志等.各淋巴细胞杀伤肿瘤细胞的初步研究[J].苏州医学院学报,1993,13(1):6-8
[34]Soygnr T,Beduk Y,Baltaci S,et al.The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using nooedjuvant M-VEC chemotherapy[J].BJU Int,1999,84(9):1069-1072
[35]张淑芬,牛立钢.应用枢复宁及胃复安控制化疗所致胃肠道反应的效果观察[J].实用肿瘤学杂志,1998,12(3):227-230
[36]郝勤岭.高剂量灭吐灵配合其他约物预防顺铂引起呕吐疗效观察[J].河南肿瘤学杂志,2000,13(5):337-338
[37]Boumpas DT,Chrousos GP,Wilder RL,et al.Glucocorticoid therapy for immune-mediated diseases:basic and clinicalcorrelates.Ann Intern Med,1993,119:1198-208
[38]von Knebel Doeberitz M,Koch S,Drzonek H,Zur Hausen H.Glucocorticoid hormones reduce the expression of major histocompatibility class I antigens on human epithelial cells.Eur J Immunol,1990,20:35-40
[39]Powell CB,Mutch DG,Kao MS,et al.Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic(NC) cell activity.Cancer,1990,65:466-72
[40]Collins JL,Patek PQ,Cohn M.Tumorigenicity and Iysis by natural killers.J Exp Med,1981,153:89-106
[1]Wani MC,Taylor HL,Wall ME,et al.Plant antitumor agents Ⅵ.The isolation and structure of taxol,a novel antileukemic and antitumor agent from Taxus brevifolia[J].J Am Chem Soc,1971,93(9):2325-2327
[2]AL-Sarrf M.Treatment of locally advanced head and neck cancer[J].C4wlcer Control,2002,9(5):387-399
[3]Panvichian R,Orth K,Day ML,et al.Paclitaxel-associated multi-minricmcleation is permitted by the inhibition of caspas sctivation:apotential early step in druy resistance[J].Cancer Res,1998,58(20):4667
[4]Li Elcma,Heikki Joensu,Jarmo Kucma,et al.Squamous cell Carcinoma is highly sensitive to taxel,a possible new radiation sensitizer[J].Acta Oldaryngal(Stockh),1995,115:340-344
[5]Roussel E,Belanger MM,Couet J.G2/Mblockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells:caveolin-1 as a marker of cytotoxicity[J].Anticancer Drugs,2004,15(10):961-967
[6]Salah-Eldin AE,Inoue S,Tsukamoto S,et al.An association of Bci-2 pheaphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment[J].Int J Cancer,2003,103(1):53-60
[7]Longguet M,Serduc R,Riva C.Implication of bax in apoptosis depends on microtubule network mobility[J].Int J Oncol,2004 25(2):309-317
[8]Stumm S,Meyer A,Lindner M,et al.Paclitaxel treatment of breat cancer cell lines modulates Fas /Fasl ligand expression and induces apoptosis which can be inhibited the CD4 receptor[J].Oncology,2004 66(2):101-111
[9]Weimin Fan,Meihua Sui and Yi Huang.Glucocoticoids selectively inhibit paclitaxel-induced apoptosis:mechanisms and its clinical impact.Current Medicinal Chemistry.2004,Feb;11(4),403-411
[10]McGuire WI,Rowinsky SK,Rosensndhein NB,et al.Taxol:aunigue antineoplastic agent with significannt activity inadvaneed ovarian epithelial neoplasms[J].Annintem Med,1989,111:273
[11]孙热,刘丽影,范魁生,等紫杉醇治疗中晚期恶性肿瘤[J],中国新药杂志,1996,5(4):252
[12]Andreasdu Bois,Handluck,Wemer Meier,et al.Carboplation plus paclutaxel as first line Chemotherapy in previously untreated advanced ovarian cancer[J].Semin Oncol,1997,24(11):28
[13]Shikawa H,Nakanishi TT,Nawa A,et al.3-hourin infusion of single-agent paclitaxel for recurrent ovarian cancer[J].Int J Clin Oncol,2001,6(3):128
[14]J Ghamande S,Lele S,Marchetti D,et al.Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer[J].Int J Gynecol Cancer,2003,13(2):142 147
[15]杨磊,樊红.紫杉类抗肿瘤药物的临床应用进展[J].中国医院用药评价与分析,2004,4(1):58
[16]苏卫,孙素华.以紫杉醇为主的联合化疗方案治疗转移性乳腺癌[J].临床肿瘤学杂志,2003,8(3):1861
[17]Henderson C,Berry DA,Demetri GD,et al.Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast caneer[J].J Clin Oncol,2003,21(6):9761
[18]陈良良,吴良村,谢长生,等.紫杉醇联合顺铂治疗Ⅲ-Ⅳ期非小细胞肺癌37例[J].实刚肿瘤学杂志,2004,18(1):31-32
[19]陈剑锋,郭文璇.紫杉醇、卡铂联合治疗非小细胞肺癌[J].河北医学,2003,9(4):308-310
[20]黄荣和,莫汉文.放射治疗合并紫杉醇治疗中晚期肺癌的临床疗效[J].重庆医学,2003,32(6):761-762
[21]Anon Scrip,1994(1880):20
[22]Forasfiere A A,Nerbera D,Taylor S G,et al.Monogr Nail Cancer Inst,1993:15-18
[23]孙明,陈一戎,王志平等.紫杉醇和维甲酸对前列腺癌PC一3细胞的作用.中华实验外科杂忠[J],2004,21(5):586-588
[24]Rowinsky EK,Burke PJ,Karp JE,et al.Phase 1 and pharmacodynamic study of taxol in refractory acute leukemias[J].Cancer Res,1989.49(16):4640-4647
[25]张湘茹,孙燕紫杉醇治疗非小细胞肺癌[J].中国新药杂志,1996,5(4):245-248
[26]Weiss RB,Donehower RC,Wreinik PH,et al.Hypersensitivity reactions from taxol[J].J Clin Oncol,1990,8(7):1263-1268
[27]Morita K,Ishimura K,Tsuruo Y,et al.Dexamethasone enhances serum deprivation-induced necrotic death of rat C6 glioma ceils through activation of glucocorticoid receptors.Brain Res,1999,816:309-16
[28]Tsai LC,Hung M W,Chang GC,et al.Apo ptosis induced by the sodium butyrate in human gastric cancer TM K-I ceils.Anticancer Res,2000,20:2441-2448
[29]Karlan BY,Jones J,Slam on DJ,et aI.Glucoconicoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.Gynecol Oncol,1994,53:70-77
[30]Ferrandina G,Scambia G,Benedetti Panici P,et al.Effects of Dexamethaso ne on the growth and epidermal growth factor receptor expresion of the OVCA 433 ovarian cancer ceils.Mol Cell Endocrinol,1992,83:183-193
[31]Braunschweiger PG,Ting HL,Schiffer LM.Correlation between GR content and the antiproliferative effect of Dexamethasone in experimental solid tumors.Cancer Res,1983,43:4757-4761
[32]McNally JG,Muller WG,Walker D,et al.The glucocorticoid receptor:rapid exchange with regulatory sites in living cells.Science,2000,287:1262-1265
[33]Wu w,Pew T,Zou M,Pang D,ConzenSD.Glucocorticoid receptor-induced MAPK phosphatase-1 expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.J Biol Chem 2005;280:4117-24
[34]Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol,2002,189:l-9
[35]Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J.Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein down regulation in MCF-7 cells.Br J Pharmacol, 2001,133:467-76
[36]Buchmann A, Willy C, Buenemann CL, Stroh C, Schmiechen A, Schwarz M. Inhibition of transforming growth factor beta1-induced hepatoma cell apoptosis by liver tumor promoters:Characterization of primary signaling events and effects on CPP32-like caspaseactivity. Cell Death Differ, 1999,6:190-200
[37]Yamamoto M, Fukuda K, Miura N, Suzuki R, Kido T, Komatsu Y. Inhibition by Dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: A possible association with Bcl-XL induction. Hepatology, 1998, 27:959-66.
[38]Gascoyne DM, Kypta RM, Vivanco MM. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-XL. J Biol Chem, 2003,278:18022-9
[39]Hammer S, Sauer B, Spika I, Schraut C, Kleuser B, Schafer-Korting M. Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1- phosphate formation. J Cell Biochem, 2004, 91:840-51
[40]Baumann S, Dostert A, Novac N, Bauer A, Schmid W, Fas SC, Krueger A, Heinzel T,Kirchhoff S, Schutz G, Krammer PH. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood, 2005, 106:617-25
[41]Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, Burn TC, Allegretto EA. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology, 2002, 143:3866-74
[42]Yerramasetti R, Gollapudi S, Gupta S. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol, 2002, 22:37-47
[43]Topper YJ, Freeman CS. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev, 1980, 60:1049-106
[44]Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol, 1995, 131:1095-103.
[45]Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: Proteinase-independent and dependent pathways. Development, 1996, 122:181-93
[46]Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res ,2000, 60:867-72
[47]Furth PA. Introduction: Mammary gland involution and apoptosis of mammary epithelialcells. J Mammary Gland Biol Neoplasia, 1999,4:123-7
[48]Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor- mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem, 2001,276:16649-54
[49]Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res, 2004, 64:1757-64
[50]Kobayashi T, Cohen P. Activation of serum- and glucocorticoid -regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositi dedependent protein kinase-1 (PDK1) and PDK2. Biochem J, 1999, 339:319-28
[51 ]Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M,Debatin KM. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res, 2003, 63: 3112-20
[52]Meihua Sui,Feng Chen, Zhi Chen and Weimin Fan Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int JCancer , 2006, 119: 712-717
[53]Pharm-Res, 2005 Apr, 22(4): 573-83